Micafungin: Difference between revisions
Carlo Banez (talk | contribs) - noting approval in the EU |
corrected IUPAC name (according to stereochemistry of the given image) |
||
| Line 1: | Line 1: | ||
{{drugbox |
{{drugbox |
||
| IUPAC_name = {5-[(1''S'',2''S'')-2-[(3''S'',6''S'',9''S'',11''R'',15''S'',18''S'',20''R'',21''R'',24''S'',25''S'',26''S'')-3-[(1''R'')-2-carbamoyl-1-hydroxyethyl]-11,20,21,25-tetrahydroxy-15-[(1''R'')-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-18-[(4-{5-[4-(pentyloxy)phenyl]-1,2-oxazol-3-yl}benzene)amido]-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0<sup>9,13</sup>]heptacosan-6-yl]-1,2-dihydroxyethyl]-2-hydroxyphenyl}oxidanesulfonic acid |
|||
| IUPAC_name = Pneumocandin A0,1-[(4R,5R)-4,5-dihydroxy-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithine]-4-[(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]-, monosodium |
|||
| image = Micafungin.svg |
| image = Micafungin.svg |
||
| width = 250 |
| width = 250 |
||
Revision as of 11:08, 21 December 2008
{{drugbox | IUPAC_name = {5-[(1S,2S)-2-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-3-[(1R)-2-carbamoyl-1-hydroxyethyl]-11,20,21,25-tetrahydroxy-15-[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-18-[(4-{5-[4-(pentyloxy)phenyl]-1,2-oxazol-3-yl}benzene)amido]-1,4,7,13,16,22-hexaazatricyclo[22.3.0.09,13]heptacosan-6-yl]-1,2-dihydroxyethyl]-2-hydroxyphenyl}oxidanesulfonic acid | image = Micafungin.svg | width = 250 | CAS_number = 235114-32-6 | ATC_prefix = J02 | ATC_suffix = AX05 | PubChem = 477468 | DrugBank = | C=56|H=71|N=9|O=23|S=1 | molecular_weight = 1270.28 g/mol | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | pregnancy_AU = | pregnancy_US = | pregnancy_category= C | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = Rx-only | routes_of_administration = Intravenous | licence_EU = Mycamine | licence_US = Micafungin }} Micafungin (trade name Mycamine) is an echinocandin antifungal drug developed by Astellas.
Micafungin is administered intravenously. It has received final approval from the United States Food and Drug Administration on March 16, 2005.
Micafungin gained approval in the European Union on April 25, 2008.
Indications
Micafungin is indicated for the treatment of candidemia, acute disseminated candidiasis, candida peritonitis, abscesses and esophageal candidiasis. On January 23, 2008, micafungin is now approved for the prophylaxis of candida infections in patients undergoing hematopoietic stem cell transplantation.
Contraindications
Known hypersensitivity to micafungin or any other ingredient contained in the formulation.
Dosage
For the treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses, the dosage of micafungin is 100 mg once daily. For the treatment of Esophageal Candidiasis, the dosage is 150 mg once daily. For the Prophylaxis of Candida Infections in HSCT Recipients, the dosage 50 mg once daily.
Dosage forms
- Mycamine 50mg for i.v.-infusion (manufacturer Astellas)
- Mycamine 100mg for i.v.-infusion (manufacturer Astellas)
- Brand names in countries other than the US may vary.
External links
- Mycamine website, run by Astellas Pharma US
- Mycamine Prescribing Information